PAI-1 gene: Pharmacogenetic association of 4G/4G genotype with bleeding after cardiac surgery - pilot study

European Journal of Anaesthesiology

Volumn 26, Issue 5, 2009, Pages 404-411

  Sirgo, Gonzalo ^a   Morales, Pablo ^b   Rello, Jordi ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Bleeding; Cardiac surgery; Genotype; Pai 1 gene; Transfusion

Indexed keywords

ANTITHROMBOCYTIC AGENT; APROTININ; COUMARIN; ETOMIDATE; FENTANYL; GUANOSINE; HEPARIN; ISOFLURANE; MIDAZOLAM; PANCURONIUM; PROTAMINE SULFATE; THIOPENTAL; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEART SURGERY; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAI 1 GENE; PHARMACOGENETICS; PILOT STUDY; POSTOPERATIVE HEMORRHAGE; RISK ASSESSMENT; SURGICAL RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; METHODOLOGY; MIDDLE AGED; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; ANTIFIBRINOLYTIC AGENTS; APROTININ; CARDIAC SURGICAL PROCEDURES; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PILOT PROJECTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POSTOPERATIVE HEMORRHAGE; TRANEXAMIC ACID;

EID: 70149090009     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e3283240412     Document Type: Article

References (34)

1. Leal-Noval SR, Rincon-Ferrari MD, Marin-Niebla A. Transfusion of erythrocyte concentrates produces a variable increment on cerebral oxygenation in patients with severe traumatic brain injury. A preliminary study. Intensive Care Med 2006; 32:1733-1740.
2. Hall TS, Sines JC, Spotnitz AJ. Haemorrhage related reexploration following open heart surgery: the impact of preoperative and postoperative coagulation testing. Cardiovasc Surg 2002; 10:146-153.
3. Merlani PG, Chenaud C, Cottini S. Point of care management of heparin administration after surgery. A randomized, controlled trial. Intensive Care Med 2006; 32:1357-1364.
4. Bevan DH. Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol 1999; 104:208.
5. Stover EP, Siegel LC, Parks R. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Institutions of the Multicenter Study of Perioperative Ischemia Research group. Anesthesiology 1998; 88:327-333.
6. Albertin A, La Colla L, Gandolfi A, et al. Greater peripheral blood flow but less bleeding with propofol versus sevoflurane during spine surgery: a possible physiologic model? Spine 2008; 33:2017-2022.
7. Marietta M, Facchini L, Pedrazzi S. Pathophysiology of bleeding in surgery. Transplant Proc 2006; 38:812-814.
8. Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30:1873-1881.
9. Lynn M, Jeroukhimov I, Klein Y. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med 2002; 28:S241 -S247.
10. Kojima T, Gando S, Morimoto Y, et al. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery. Thromb Res 2001; 104:301 -307.
11. Kang H-M, Kalnoski MH, Frederick M, Wayne WL. The kinetics of plasmin inhibition by aprotinin in vivo. Thromb Res 2005; 115:327-340.
12. Iribarren JL, Jimenez JJ, Hernandez D, et al. Postoperative bleeding in cardiac surgery. The role oftranexamic acid in patients homozygous for the 5G polymorphism of the plasminogen activator inhibitor-1 gene. Anesthesiology 2008; 108:596-602.
13. Dawson S, Hamsten A, Wiman B, et al. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 gene. Arterioscler Thromb 1991; 11:183-190.
14. Eriksson P, Kallin B, Van't Hoof FM. Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92:1851 - 1855.
15. Burzotta F, DiCastelnuovo A, Amore A. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost 1998; 79:354-358.
16. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials.J Thorac Cardiovasc Surg 2004; 128:442-448.
17. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001; 41 :101 -121.
18. Sirgo G, Pérez-Vela JL, Morales P, et al. Relation between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery.Intensive Care Med 2006;32:668-675.
19. Filsoufi F, Castillo JG, Rahmanian PB. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII. Ann Thorac Surg 2006; 82:1779-1783.
20. Karkouti K, Beattie S, Wijeysundera DN. Recombinant factor VII for intractable blood loss after cardiac surgery: a propensity score-matched case control analysis. Transfusion 2005; 45:26 -34.
21. Gogbashian A, Sedrakyan A, Treasure T. EuroSCORE: a systematic review of international performance. Eur J Cardiothorac Surg 2003; 23:360-367.
22. Calafiore AM, Di Mauro M, Canosa C. Early and late outcome of myocardial revascularization with and without cardiopulmonary bypass in high risk patients (EuroSCORE ≥6). Eur J Cardiothorac Surg 2003; 24:953-960.
23. Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83 (Suppl 5):S27-S86.
24. Benza RL, Grenett HE, Bourge RC. Gene polymorphism for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease. Circulation 1998; 98:2248-2254.
25. Parr KG, Patel MA, Dekker R. Multivarite predictorsofblood productusein cardiac surgery. J Cardiothorac Vasc Anesth 2003; 2:176-181.
26. Karthik S, Grayson AD, McCarron EE. Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes and the effect of time delay. Ann Thorac Surg 2004; 2:527-534.
27. Aquilante CL, Langaee TY, Lopez LM. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006; 79:291 -302.
28. Hermans PWM, Hibberd ML, Booy R. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet 1999; 354:556-560.
29. Menges T, Hermans PW, Little SG. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis ofseverelyinjured patients. Lancet 2001; 357:1096-1097.
30. Donahue BS, Gailani D, Higgins MS. Factor V Leiden protects against blood loss and transfusion after cardiac surgery. Circulation 2003; 107:1003-1008.
31. Welsby IJ, Podgoreanu MV, Phillips-Bute B. Genetic factors contribute to bleeding after cardiac surgery. J Thromb Haemost 2005; 3:1206-1212.
32. Boehm J,Grammer JB,Lehnert F.Factor V Leidendoes not affect bleeding in aprotinin recipientsafter cardio pulmonary by pass. Anesthesiology 2007; 106:681-686.
33. Wells PS. Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature. Am J Ther 2002; 9:377-388.
34. Matsubara Y, Hayakawa T, Tsuda T. Angiotensin converting enzyme insertion/deletion polymorphism is associated with plasma antigen levels of plasminogen activator inhibitor-1 in healthy Japanese population. Blood Coagul Fibrinolysis 2000; 11 :115-120.